"uuid:ID","description","label","name","id","rationale","instanceType"
"81711064-a3bf-42ee-874e-bb1ef61de508","The main design for the study","","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
